Itaconic Acid 99.5% Min C5h6o4 Factory Supply Good Price 97-65-4

The "developer master" iodine contrast agent belongs to the "small variety" of the API plate, but it faces "big demand". With the deepening of the national medical insurance and the wide application of medical imaging technology, the market demand of contrast media in China is strong. After statistics, from 2016 to 2021, our country hospital market mainly contrast agent market size increased from 9.497 billion yuan to 16.794 billion yuan, compound annual growth rate reached 12.1%, far higher than global growth.

Looking back at history, since 2018, the import price of iodine (the main raw material of iodine contrast agent) in China has risen rapidly. However, with the expansion of large-scale upstream iodine supply enterprises and the release of small and medium-sized iodine minerals, the current price of iodine raw materials has entered a downward cycle. From $71 / kg in February 2023 to $65 / kg in February 2024, it is expected to continue to decline. The decrease of iodine price will effectively improve the gross profit margin of downstream iodine contrast agent API companies, and the "invisible champion" of downstream iodine contrast agent API in China is worthy of attention.

Typical of a leading enterprise with the integrated layout of iodine contrast agent "intermediates + apis + preparations", it is expected that the benefit cost side will improve in 2024, the performance elasticity is obvious, and the decline in iodine price is expected to increase the company's profits. In March this year, the company also announced that it would raise funds for capacity expansion against the trend, which also highlights the company's confidence in the subsequent industry boom, helping the company to consolidate its leading position in the industry.

At present, the company has completed the integrated layout of "intermediates + apis + preparations" around iodine contrast agents, and the production capacity of the three core apis is about 2,200 tons, and the leading position of iodine contrast agents is stable. At present, the global demand for iodine contrast agent apis exceeds 10,000 tons, and most of them are dominated by original research, and the company has huge replacement space. The company main business of the CMO/CDMO around iodine chemistry, and based on this platform, extended to fall blood pressure, fall blood sugar, allergy, antivirus, and other areas of the innovation medicine, is expected to expand new business growth point in the future.